Emergent BioSolutions SVP gets option grant, pays taxes
Emergent BioSolutions senior vice president William Hartzel reported routine equity compensation transactions.
Rhea-AI Filing Summary
Emergent BioSolutions senior vice president William Hartzel reported routine equity compensation transactions. On March 5, 2026, 9,493 shares of common stock were disposed of at $8.44 per share to cover taxes tied to restricted stock unit vesting, leaving him with 87,188 shares of common stock held directly.
On March 3, 2026, he received a grant of 44,834 employee stock options, increasing his directly held options to 259,545. The grant is scheduled to vest in three equal installments beginning on the day prior to each anniversary of the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 9,493 | $8.44 | $80K |
| Grant/Award | Employee Stock Option (Right to buy) | 44,834 | $0.00 | $0.00 |
Footnotes (2)
- F1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
- F2. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did EBS executive William Hartzel report on this Form 4?
What are the details of the stock options granted to EBS SVP William Hartzel?
What role does William Hartzel hold at Emergent BioSolutions (EBS)?
AI-generated analysis. How Rhea-AI works. Not financial advice.